Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…
Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE + nimacimab in obesity
Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE +…
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration…
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan Professional…
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing Professional…
Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative
Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative…
Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS platform
Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD…
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary…
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase…